Symbols / GOVX Stock $2.23 +10.95% GeoVax Labs, Inc.

Healthcare • Biotechnology • United States • NCM
GOVX (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Mr. David Alan Dodd
Exch · Country NCM · United States
Market Cap 7.75M
Enterprise Value 6.87M
Income -21.37M
Sales 852.28K
FCF (ttm) -11.10M
Book/sh 0.17
Cash/sh 0.37
Employees 19
Insider 10d —
IPO Sep 25, 2020
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E -2.59
PEG —
P/S 9.09
P/B 12.74
P/C —
EV/EBITDA -0.32
EV/Sales 8.06
Quick Ratio 0.56
Current Ratio 1.06
Debt/Eq 79.91
LT Debt/Eq —
EPS (ttm) -13.82
EPS next Y -0.86
EPS Growth —
Revenue Growth —
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-03-23
Earnings (prior) 2026-05-14
ROA -194.59%
ROE -5.09%
ROIC —
Gross Margin 0.00%
Oper. Margin -25.23%
Profit Margin 0.00%
Shs Outstand 3.47M
Shs Float 3.47M
Insider Own 0.10%
Instit Own 9.85%
Short Float 8.80%
Short Ratio 2.55
Short Interest 254.32K
52W High 34.75
vs 52W High -93.58%
52W Low 0.96
vs 52W Low 131.57%
Beta —
Impl. Vol. —
Rel Volume 1.21
Avg Volume 3.77M
Volume 4.55M
Target (mean) $77.50
Tgt Median $10.00
Tgt Low $10.00
Tgt High $212.50
# Analysts 3
Recom Strong_buy
Prev Close $2.01
Price $2.23
Change 10.95%
About

GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms in the United States. It develops GEO-CM04S1, a vaccine candidate that is in Phase 2 clinical trial for the treatment of preventive COVID-19; Gedeptin, a novel patented product/technology for the treatment of solid tumors, and Phase 1/2 clinical trial for the treatment of advanced head and neck squamous cell carcinoma; and GEO-CM02, a pan-coronavirus vaccine. In addition, the company offers GEO-MVA-MUC1, a vaccine candidate, which is in preclinical trial for the treatment of solid tumor cancers; GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of Zika; GEO-EMO1-Z, which is in preclinical trial for the treatment of Ebola Zaire; GEO-EMO1-S, which is in preclinical trial for the treatment of Ebola Sudan; GEO-MM01 treatment for marburg; and GEO-MVA for the treatment of Mpox and small pox. It has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; and the U.S. Department of Defense. GeoVax Labs, Inc. was incorporated in 1988 and is based in Smyrna, Georgia.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$77.50
Mean price target
2. Current target
$2.23
Latest analyst target
3. DCF / Fair value
$-57.53
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$2.23
Low
$10.00
High
$212.50
Mean
$77.50

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-04-16 main D. Boral Capital Hold → Hold $1
2026-02-19 down D. Boral Capital Buy → Hold —
2026-01-21 main D. Boral Capital Buy → Buy $6
2025-11-19 main D. Boral Capital Buy → Buy $6
2025-09-26 main D. Boral Capital Buy → Buy $9
2025-08-07 main D. Boral Capital Buy → Buy $9
2025-07-29 main D. Boral Capital Buy → Buy $9
2025-07-17 main D. Boral Capital Buy → Buy $9
2025-06-16 main D. Boral Capital Buy → Buy $9
2025-05-02 main D. Boral Capital Buy → Buy $9
2025-04-16 reit HC Wainwright & Co. Buy → Buy $8
2025-04-15 main D. Boral Capital Buy → Buy $14
2025-04-10 main D. Boral Capital Buy → Buy $18
2025-03-28 main D. Boral Capital Buy → Buy $18
2025-02-27 main D. Boral Capital Buy → Buy $18
2025-01-31 main D. Boral Capital Buy → Buy $18
2025-01-16 main D. Boral Capital Buy → Buy $18
2024-12-18 main D. Boral Capital Buy → Buy $18
2024-11-20 reit HC Wainwright & Co. Buy → Buy $8
2024-11-19 main D. Boral Capital Buy → Buy $18
News
RSS: Latest GOVX news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2025-10-17 SPENCER JOHN N JR Director — 10,000 $0.55 $5,498
2025-08-07 MCKEE KELLY T JR. Officer — 1,107 $0.67 $742
2025-04-10 SHARKEY JOHN W PH.D. Officer — 6,000 $0.99 $5,940
2025-04-01 DODD DAVID A Chief Executive Officer — 10,000 $1.08 $10,800
2025-03-31 REYNOLDS MARK W Chief Financial Officer — 6,800 $1.08 $7,343
2024-08-09 DODD DAVID A Chief Executive Officer — 8,000 $1.95 $15,600
2024-02-22 DODD DAVID A Chief Executive Officer — 8,729 $2.15 $19,781
2024-02-07 REYNOLDS MARK W Chief Financial Officer — 2,000 $2.77 $5,540
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
2.49
-37.06%
3.95
0.00
-100.00%
0.08
Operating Revenue
2.49
-37.06%
3.95
0.00
-100.00%
0.08
Operating Expense
24.13
-17.08%
29.10
+8.81%
26.74
+89.53%
14.11
Research And Development
18.12
-23.58%
23.71
+14.44%
20.72
+127.11%
9.12
Selling General And Administration
6.01
+11.54%
5.39
-10.58%
6.02
+20.77%
4.99
General And Administrative Expense
6.01
+11.54%
5.39
-10.58%
6.02
+20.77%
4.99
Other Gand A
6.01
+11.54%
5.39
-10.58%
6.02
+20.77%
4.99
Total Expenses
24.13
-17.08%
29.10
+8.81%
26.74
+89.53%
14.11
Operating Income
-21.64
+13.94%
-25.14
+5.98%
-26.74
-90.63%
-14.03
Total Operating Income As Reported
-21.64
+13.94%
-25.14
+5.98%
-26.74
-90.63%
-14.03
EBITDA
-21.40
+13.99%
-24.88
+3.93%
-25.89
-85.31%
-13.97
Normalized EBITDA
-21.40
+13.99%
-24.88
+3.93%
-25.89
-85.31%
-13.97
Reconciled Depreciation
0.07
-27.90%
0.10
+28.58%
0.07
+31.78%
0.06
EBIT
-21.46
+14.04%
-24.97
+3.84%
-25.97
-85.10%
-14.03
Total Unusual Items
—
—
—
0.00
Total Unusual Items Excluding Goodwill
—
—
—
0.00
Special Income Charges
—
—
—
0.00
Other Special Charges
—
—
—
—
Net Income
-21.46
+14.11%
-24.99
+3.75%
-25.97
-85.20%
-14.02
Pretax Income
-21.46
+14.11%
-24.99
+3.75%
-25.97
-85.20%
-14.02
Net Non Operating Interest Income Expense
0.17
+14.67%
0.15
-80.42%
0.78
+10333.89%
0.01
Interest Expense Non Operating
0.00
-100.00%
0.02
0.00
0.00
Net Interest Income
0.17
+14.67%
0.15
-80.42%
0.78
+10333.89%
0.01
Interest Expense
0.00
-100.00%
0.02
0.00
0.00
Interest Income Non Operating
0.17
+0.53%
0.17
-77.67%
0.78
+10333.89%
0.01
Interest Income
0.17
+0.53%
0.17
-77.67%
0.78
+10333.89%
0.01
Other Income Expense
—
—
—
—
Tax Rate For Calcs
0.00
0.00
0.00
0.00
Tax Effect Of Unusual Items
0.00
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
-21.46
+14.11%
-24.99
+3.75%
-25.97
-85.20%
-14.02
Net Income From Continuing Operation Net Minority Interest
-21.46
+14.11%
-24.99
+3.75%
-25.97
-85.20%
-14.02
Net Income From Continuing And Discontinued Operation
-21.46
+14.11%
-24.99
+3.75%
-25.97
-85.20%
-14.02
Net Income Continuous Operations
-21.46
+14.11%
-24.99
+3.75%
-25.97
-85.20%
-14.02
Normalized Income
-21.46
+14.11%
-24.99
+3.75%
-25.97
-85.20%
-14.02
Net Income Common Stockholders
-21.46
+14.11%
-24.99
+3.75%
-25.97
-85.20%
-14.02
Diluted EPS
-22.40
+81.40%
-120.46
+66.28%
-357.25
-14.78%
-311.25
Basic EPS
-22.40
+81.40%
-120.46
+66.28%
-357.25
-14.78%
-311.25
Basic Average Shares
0.96
+361.94%
0.21
+185.43%
0.07
+60.60%
0.05
Diluted Average Shares
0.96
+361.94%
0.21
+185.43%
0.07
+60.60%
0.05
Diluted NI Availto Com Stockholders
-21.46
+14.11%
-24.99
+3.75%
-25.97
-85.20%
-14.02
Line Item Trend 2023-12-31
Total Assets
9.28
Current Assets
7.89
Cash Cash Equivalents And Short Term Investments
6.45
Cash And Cash Equivalents
6.45
Receivables
0.00
Other Receivables
—
Prepaid Assets
1.43
Other Current Assets
—
Total Non Current Assets
1.40
Net PPE
0.21
Gross PPE
0.89
Accumulated Depreciation
-0.68
Properties
0.00
Buildings And Improvements
—
Machinery Furniture Equipment
0.77
Leases
0.12
Goodwill And Other Intangible Assets
0.07
Other Intangible Assets
0.07
Non Current Prepaid Assets
1.12
Other Non Current Assets
1.19
Total Liabilities Net Minority Interest
3.52
Current Liabilities
3.52
Payables And Accrued Expenses
3.52
Payables
2.80
Accounts Payable
2.80
Current Accrued Expenses
0.72
Current Debt And Capital Lease Obligation
—
Current Capital Lease Obligation
—
Total Non Current Liabilities Net Minority Interest
0.00
Long Term Debt And Capital Lease Obligation
—
Long Term Capital Lease Obligation
—
Other Non Current Liabilities
—
Stockholders Equity
5.76
Common Stock Equity
5.76
Capital Stock
0.00
Common Stock
0.00
Preferred Stock
—
Share Issued
0.08
Ordinary Shares Number
0.08
Treasury Shares Number
0.00
Additional Paid In Capital
110.13
Retained Earnings
-104.36
Total Equity Gross Minority Interest
5.76
Total Capitalization
5.76
Working Capital
4.37
Invested Capital
5.76
Total Debt
—
Capital Lease Obligations
—
Net Tangible Assets
5.69
Tangible Book Value
5.69
Non Current Accrued Expenses
—
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-21.47
+12.97%
-24.68
+1.98%
-25.17
-32.28%
-19.03
Cash Flow From Continuing Operating Activities
-21.47
+12.97%
-24.68
+1.98%
-25.17
-32.28%
-19.03
Net Income From Continuing Operations
-21.46
+14.11%
-24.99
+3.75%
-25.97
-85.20%
-14.02
Depreciation Amortization Depletion
0.07
-27.90%
0.10
+28.58%
0.07
+31.78%
0.06
Depreciation
0.07
—
0.07
+31.78%
0.06
Depreciation And Amortization
0.07
-27.90%
0.10
+28.58%
0.07
+31.78%
0.06
Stock Based Compensation
1.12
+110.95%
0.53
-50.82%
1.07
+19.17%
0.90
Operating Gains Losses
—
—
—
—
Gain Loss On Investment Securities
—
—
—
—
Change In Working Capital
-1.19
-288.35%
-0.31
+13.70%
-0.36
+94.03%
-5.97
Change In Receivables
0.66
+200.00%
-0.66
0.00
-100.00%
0.05
Change In Prepaid Assets
-0.41
-17.75%
-0.35
-207.50%
-0.11
+90.18%
-1.17
Change In Payables And Accrued Expense
-1.47
-255.25%
-0.41
+66.41%
-1.23
+54.31%
-2.69
Change In Other Working Capital
—
—
—
-2.16
Change In Other Current Assets
0.03
-97.53%
1.12
+13.21%
0.99
+145.60%
-2.16
Investing Cash Flow
-0.03
-33.69%
-0.02
+57.80%
-0.05
+63.54%
-0.13
Cash Flow From Continuing Investing Activities
-0.03
-33.69%
-0.02
+57.80%
-0.05
+63.54%
-0.13
Net PPE Purchase And Sale
-0.03
-33.69%
-0.02
+57.80%
-0.05
+63.54%
-0.13
Purchase Of PPE
-0.03
-33.69%
-0.02
+57.80%
-0.05
+63.54%
-0.13
Capital Expenditure
-0.03
-33.69%
-0.02
+57.80%
-0.05
+63.54%
-0.13
Financing Cash Flow
19.08
-19.66%
23.75
+484.64%
4.06
-88.51%
35.35
Cash Flow From Continuing Financing Activities
19.08
-19.66%
23.75
+484.64%
4.06
-88.51%
35.35
Net Issuance Payments Of Debt
0.00
+100.00%
-0.01
0.00
0.00
Issuance Of Debt
0.00
-100.00%
0.14
0.00
—
Repayment Of Debt
0.00
+100.00%
-0.15
0.00
0.00
Long Term Debt Issuance
—
—
—
—
Long Term Debt Payments
—
—
—
0.00
Net Long Term Debt Issuance
—
—
—
0.00
Short Term Debt Issuance
0.00
-100.00%
0.14
0.00
—
Short Term Debt Payments
0.00
+100.00%
-0.15
0.00
0.00
Net Short Term Debt Issuance
0.00
+100.00%
-0.01
0.00
0.00
Net Common Stock Issuance
18.92
-11.56%
21.40
0.00
-100.00%
27.73
Repurchase Of Capital Stock
—
—
—
0.00
Proceeds From Stock Option Exercised
0.16
-93.40%
2.37
-41.73%
4.06
-46.73%
7.63
Changes In Cash
-2.42
-156.04%
-0.95
+95.53%
-21.16
-230.71%
16.19
Beginning Cash Position
5.51
-14.66%
6.45
-76.63%
27.61
+141.71%
11.42
End Cash Position
3.09
-43.97%
5.51
-14.66%
6.45
-76.63%
27.61
Free Cash Flow
-21.50
+12.94%
-24.70
+2.09%
-25.22
-31.61%
-19.16
Common Stock Issuance
18.92
-11.56%
21.40
0.00
-100.00%
27.73
Issuance Of Capital Stock
18.92
-11.56%
21.40
0.00
-100.00%
27.73
Net Preferred Stock Issuance
—
—
—
0.00
Preferred Stock Issuance
—
—
—
—
Preferred Stock Payments
—
—
—
0.00
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category